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The ink was barely dry on my editorial for the previous issue of Reviews in 
Medical Virology than another piece of information was published relevant to 
screening for congenital CMV infection. Gantt and colleagues(1) have 
calculated the potential cost effectiveness of screening in the USA, divided 
into two major parts; selective testing of those neonates who fail national 
screening programmes for hearing loss; universal screening of all newborns. 
 
To begin with, they estimated the costs associated with congenital CMV, 
based on the known natural history. A strength of their article is that they used 
the costs accepted by Medicare when reimbursing current expenditure. They 
allowed $10 per PCR test, one ophthalmology examination and cranial 
ultrasound in all neonates with congenital CMV with an estimate that 20% 
would require an MRI scan in addition. A course of valganciclovir would be 
given to those born with symptoms, so they included the cost of the drug plus 
monitoring for neutropenia. Audiology assessments would be performed every 
six months to the age of six years and they assumed that 50% of babies with 
bilateral, severe sensorineural hearing loss would need cochlear implants. 
They did not include administrative costs for running the programme, 
assuming that the current system could cope.(1) 
 
They next looked at the monetary value of benefits that would accrue to 
society through screening, broken into two broad categories. First, it is well 
known that the young brain develops according to the stimuli it receives. This 
means that neonates who are profoundly deaf will have underdeveloped 
speech receptive areas so that, even if their perception of sound is 
subsequently improved through cochlear implantation, the brain will have 
impaired ability to process the signals received. Compensation for early 
diagnosis of hearing loss of any cause leads to a 24% improvement in scores 
for language, so this is the figure they used in the calculations of benefits for 
CMV.(2) For those children whose hearing is intact at birth but subsequently 
deteriorates, an estimate of a 12% improvement in language was used. 
Second, they estimated the benefits attributable to treatment with ganciclovir 
or its prodrug valganciclovir. Two randomised controlled trials provide 
evidence; six weeks of intravenous ganciclovir compared to controls 
randomised to no treatment which led to a six-week course of this drug being 
adopted as the standard of care.(3) A later study gave valganciclovir for six 
weeks to all followed by valganciclovir or placebo to complete six months of 
therapy.(4) The longer course provided a better clinical outcome with 
significantly improved hearing measured 12 months and 24 months after 
study entry and so is now the standard of care for neonates born with 
symptoms. Because the clinical progression of sensorineural hearing loss 
caused by CMV fluctuates with time, Gantt and colleagues subtracted the 
improvements seen in the control group to give an estimate that 50% of 
neonates will have hearing improvement after treatment for six months. The 
average degree of improvement was assumed to be one grade of hearing 
loss i.e. profound to severe, severe to moderate, moderate to mild or mild to 
normal.(1) Of note, both of these randomised clinical trials recruited babies 
born with symptoms; no study has recruited and randomised children born 
with isolated sensorineural hearing loss caused by CMV, so clinical practice 
on treatment varies. To address this, the authors calculated benefits where 
screened children found to have congenital CMV infection were treated only if 
they had other stigmata of symptomatic congenital CMV (such as 
microcephaly or intracranial calcifications) and used separate calculations to 
estimate the benefits of treating those with isolated sensorineural hearing loss 
in addition. Although CMV also causes microcephaly, the authors did not 
claim a financial benefit for any improvement in intellectual function following 
early diagnosis and treatment because, although the results from clinical trials 
are encouraging, more data are required to allow a robust cost saving to be 
calculated. Savings were calculated to come from reduced educational needs 
such as speech therapy ($7,000 to $19,000 depending on age) and 
equipment needs (ranging from $1,400 for hearing aids to $100,000 for a 
cochlear implant). Finally, they calculated these direct benefits alone or 
together with estimates of social costs of impaired productivity caused by 
hearing loss. They used the figure of $926,000 for lost productivity where 
employees were profoundly deaf, but a figure of zero was used when the 
sensorineural hearing loss was only mild or moderate.(5) 
 
Effectiveness and cost effectiveness can be presented in different ways. We 
would like to know how much of the clinic workload of dealing with children 
with severe or profound sensorineural hearing loss could be reduced by 
screening for congenital CMV. We would like to know how much it costs to 
diagnose a case of congenital CMV, to diagnose a case of sensorineural 
hearing loss caused by CMV and how much to prevent one cochlear implant 
needed because of the sensorineural hearing loss caused by congenital CMV. 
 
Gantt and colleagues estimate that a selective screening programme would 
reduce clinic workload by 4.2%, increasing to 9.7% if children with isolated 
sensorineural hearing loss were treated in addition. For universal screening, 
the corresponding figures were 7.5% and 13%. Assuming that only 
symptomatic cases at birth would be treated (to reflect current clinical 
practice), the costs to identify one case of congenital infection, one case of 
CMV-related hearing loss and to prevent one cochlear implant were $566, 
$975 and $39,401 respectively for selective screening. The corresponding 
costs for universal screening were $2,000, $27,460 and £4,064,157. 
 
When these costs were compared to the savings in direct costs, there was a 
net saving of $0.90 per case through selective screening which increased to a 
saving of $10.66 when indirect costs were included. The corresponding 
figures for universal screening were a cost of $10.86 and a saving of $21.34. 
When treatment for those with isolated sensorineural hearing loss was 
included, there was a net saving of $4.95 for selective screening which 
improved to $27.31 when indirect costs were incorporated. The equivalent 
figures for universal screening were a cost of $6.83 and a saving of $37.97. 
 
 
 
 
All of these costs are well within those generally accepted for a screening 
programme for other conditions and the combinations of parameters that lead 
to overall cost savings to society are clearly welcome. 
 
So, where does this new research leave us? This paper will undoubtedly be 
influential, because screening committees have been waiting for information 
on cost-effectiveness before deciding what to do about congenital CMV 
infection. Some commentators may feel that the authors have been too 
optimistic (assuming no administration costs) or too pessimistic (assuming no 
financial benefits from improved intellectual function). Some will want to stick 
to conventional medical practice by treating only those with classical 
symptoms at birth, while others will want to get on and include treatment for 
cases with isolated hearing loss in addition, citing the evidence that 
valganciclovir predominantly reduces future hearing loss rather than repairing 
damage to hearing that has already occurred.(4) This genuine difference in 
clinical opinion and practice should not be a barrier to action; instead, it 
should stimulate members of steering committees to press for pilot studies to 
define the remaining uncertainties in more detail. They should be encouraged 
by the finding that any combination of the parameters reported for CMV will be 
more cost-effective than existing screening programmes they have supported 
in the past, so they are unlikely to make a mistake whatever decision they 
take. There are no bad decisions here, only a series of good decisions, and 
diversity of potential approaches should be welcomed. For example, different 
States in the USA could elect for universal screening where selective 
screening has already started as a way of identifying the incremental benefits 
of screening all births, including identification of late onset cases of 
sensorineural hearing loss caused by CMV. Alternatively, they could introduce 
universal screening de novo. In either case, screening could be based on 
testing saliva or testing dried blood spots using improved PCR methods. (6-8) 
Comparison of the results from these different States would help inform the 
type of screening programme that should be recommended throughout the 
USA and put robust values on the estimates of medical and financial benefits 
that can be delivered in practice.  
 
What are the realistic prospects of this coming to pass? As the USA at last 
comes out of the decade-long recession, politicians are said to be short of 
"shovel ready" infrastructure projects to spend money on. Here is one project 
that is likely to be a great investment, because it is projected to be cost saving 
for society irrespective of what option is selected; so start shovelling dollars in 
the direction of CMV screening. 
 
 
PD Griffiths 
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